Although potentially linked to the presumed mode of action of GLP-2, CASK is, therefore, currently not a likely candidate as a routine biomarker for small intestinal function in SBS patients. Here, GCG is linked to macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.